UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of report (Date of earliest event reported):
                               September 17, 2008

                           HEMISPHERX BIOPHARMA, INC.
               (Exact Name of Registrant as Specified in Charter)

                           Delaware 0-27072 52-0845822
             (State or Other Jurisdiction (Commission (IRS Employer
               of Incorporation) File Number) Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania, 19103
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities
 Act (17 CFR230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
 Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
 Act (17 CFR 240.13e-4(c))








Section 8 - Other Events
Item 8.01 Other Events.

On September 17, 2008, we adjourned our annual stockholders'  meeting to Friday,
October 17, 2008 at 10:00 a.m. at the Crown  Plaza  Hotel,  1800 Market  Street,
Philadelphia  Pennsylvania  19103.  The meeting has been  adjourned  because the
required  quorum of a majority of the shares eligible to vote at the meeting was
not present at the meeting.

For more information,  please see the September 17, 2008 press released filed as
exhibit 99.1 to this report.

Item 9.01.        Financial Statements and Exhibits.

              (c) Exhibits:

                    99.1          Press Release dated September 17, 2008



                                Signatures

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Date:  September 17, 2008

                                               HEMISPHERX BIOPHARMA, INC.

                                               /s/ William A. Carter,
                                               ----------------------
                                               William A. Carter, M.D.,
                                               Chief Executive Officer





                                                           Exhibit 99.1



Company/Investor Contact:
Dianne Will                                         Sean Collins, Sr. Partner
Hemispherx Biopharma, Inc.                          CCG Investor Relations
518-398-6222                                        310-477-9800
ir@hemispherx.net

HEMISPHERX BIOPHARMA,  INC. ADJOURNS STOCKHOLDER MEETING DUE TO LACK OF A QUORUM
                              TO OCTOBER 17, 2008

     Philadelphia,  PA, Sept. 17, 2008--Hemispherx  Biopharma,  Inc. (AMEX, HEB)
announced today that it adjourned its annual stockholders'  meeting, held today,
to Friday, October 17, 2008 at 10:00 a.m. at the Crowne Plaza Hotel, 1800 Market
Street, Philadelphia, Pennsylvania 19103.

     The meeting has been adjourned  because a quorum of shares eligible to vote
at the meeting was not present at the meeting.

     The record date remains  July 21, 2008.  The purposes for which the meeting
is being held remain the same as those listed in the Company's  Notice of Annual
Meeting of August 1,  2008.  Stockholders  should  address  questions  about the
meeting to the Company's proxy solicitors at MacKenzie Partners,  Inc., at (800)
322-2885 or (212) 929-5500.


About Hemispherx Biopharma

Hemispherx  Biopharma,  Inc.  is a  specialty  pharma  company  engaged  in  the
manufacture  and clinical  development  of new drug  entities  for  treatment of
seriously debilitating disorders. Hemispherx's flagship products include Alferon
N Injection(R)  (FDA approved for a category of sexually  transmitted  diseases)
and the experimental  therapeutics  Ampligen(R) and Oragens(R).  Ampligen(R) and
Oragens(R) represent experimental RNA nucleic acids being developed for globally
important debilitating diseases and disorders of the immune system. Hemispherx's
platform  technology  includes  large and small agent  components  for potential
treatment  of  various  severely  debilitating  and life  threatening  diseases.
Hemispherx has in excess of 90 issued patents  comprising its core  intellectual
property estate and a fully commercialized product (Alferon N Injection(R)). The
Company  wholly  owns and  exclusively  operates a GMP  certified  manufacturing
facility in the United  States for  commercial  products.  For more  information
please visit www.hemispherx.net

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; Similarly, the completion of
NDA filing process with Ampligen(R) does not imply that the product will ever be
approved commercially.